A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded study of three doses of MSDC-0602K or placebo given
orally once daily to subjects with biopsy proven NASH with fibrosis and no cirrhosis.
Phase:
Phase 2
Details
Lead Sponsor:
Cirius Therapeutics, Inc. Octeta Therapeutics, LLC